Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

WuXi Reports Record Revenues, CapEx Spending

publication date: Nov 14, 2014
WuXi PharmaTech reported Q3 revenues were up 18% to $173.6 million, a record, while GAAP earnings were higher by a smaller 8% at $0.45. The company has "strong momentum," according to Dr. Ge Li, Chairman and CEO. To keep growing, it increased Capital Expenditures from $56 million last year to $100 million in 2014, and will spend even more next year to increase manufacturing capacity, WuXi's fastest growing business sector. And WuXi now has 500 employees devoted to biologic drug discovery, another major growth area. More details....

Stock Symbol: (NYSE: WX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital